Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma
* To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival.
* Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical and radiological) response rate and the safety of the treatment.
Head and Neck Neoplasms
DRUG: docetaxel and cisplatin
Complete response rate after neoadjuvant chemotherapy, From the start date of the treatment to the date of first documented progression of disease or at least until 2 years follow-up period
Percentage of patients whose is disease controlled locally or regionally, from the start date of the treatment to the date of first documented local or regional tumor progression|Median length of overall survival, time interval from the date of treatment to the date of death or at least until 2 years follow-up period|Median length of disease free survival, time interval from the date of treatment to the date of death or at least until 2 years follow-up period|Percentage of alive patients without metastatis, from the start date of the treatment to the date of first documented distant metastasis
* To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival.
* Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical and radiological) response rate and the safety of the treatment.